Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

6 Jun 2018 07:00

RNS Number : 4052Q
Instem plc
06 June 2018
 

6 June 2018

Instem plc

("Instem")

 

Contract win

 

Leading Fortune 500 Company adopts Instem's Samarind RMS solution for its worldwide medical products regulatory tracking system

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that a leading Fortune 500 medical products and pharmaceuticals company has adopted Instem's Samarind RMS Software-as-a-Service ("SaaS") solution. The contract is worth approximately US$750,000 incorporating both perpetual license and SaaS revenue streams with c. 80% of the contract value being recognised in 2018 and annual recurring revenue of US$169,000.

 

Samarind RMS provides medical device and pharmaceutical companies with a smarter way to manage their Product Information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. The product is optimised to enable these companies to register and track their regulated products worldwide by maintaining a single integrated database of all relevant information, which is then used to update regulators as products change over time. The comprehensive functionality provided by Samarind RMS enables customers to systematically define and execute complex regulatory activities across a globally dispersed workforce whilst providing a single place to find, analyse and act on a wealth of product and regulatory information.

 

Phil Reason, CEO of Instem plc, said: "This contract win with a global company, which ranks among the top 25 on the Fortune 500, continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field. We are very pleased to be delivering this as a SaaS agreement."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKPDKABKDAAK
Date   Source Headline
3rd Oct 20233:20 pmRNSHolding(s) in Company
3rd Oct 20232:25 pmRNSForm 8.3 -INSTEM PLC
3rd Oct 20232:10 pmPRNForm 8.3 - Instem Plc
3rd Oct 202312:31 pmRNSForm 8.3 - Instem PLC
3rd Oct 202312:20 pmRNSForm 8.3 - Instem PLC amendment
3rd Oct 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
3rd Oct 202310:04 amRNSForm 8.3 - Instem Plc
2nd Oct 20232:53 pmRNSForm 8.3 - INSTEM PLC
2nd Oct 20232:37 pmGNWForm 8.3 - Instem Plc
2nd Oct 20231:50 pmRNSForm 8.3 - Instem PLC
2nd Oct 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
2nd Oct 20239:02 amRNSForm 8.5 (EPT/RI)
29th Sep 20232:59 pmGNWForm 8.3 - Instem PLC
29th Sep 20232:08 pmPRNForm 8.3 - Instem Plc
29th Sep 20232:04 pmGNWForm 8.3 - [Instem plc - 28 09 2023] - (CGAML)
29th Sep 202310:18 amRNSForm 8.5 (EPT/RI)
27th Sep 20235:28 pmRNSHolding(s) in Company
27th Sep 20233:27 pmRNSForm 8.3 - Instem PLC
27th Sep 20231:20 pmPRNForm 8.3 - Instem Plc
27th Sep 202310:03 amRNSForm 8.5 (EPT/RI)
27th Sep 20239:50 amRNSForm 8.3 - Instem Plc
26th Sep 202312:03 pmRNSForm 8.5 (EPT/RI)
25th Sep 20234:24 pmRNSPublication of Scheme Document
25th Sep 20233:27 pmRNSForm 8.3 - Instem PLC
25th Sep 20239:29 amRNSForm 8.3 - Instem Plc
25th Sep 20239:24 amRNSForm 8.5 (EPT/RI)
22nd Sep 202311:52 amRNSForm 8.5 (EPT/RI)
21st Sep 20231:07 pmRNSForm 8.3 - Instem plc
21st Sep 202311:51 amRNSForm 8.5 (EPT/RI)
20th Sep 202310:07 amRNSForm 8.5 (EPT/RI)
20th Sep 20239:00 amRNSForm 8.3 - Instem Plc
19th Sep 20237:00 amRNSGrant of PDMR Options
18th Sep 20233:27 pmRNSForm 8.3 - Instem PLC
18th Sep 202310:09 amRNSForm 8.5 (EPT/RI)
15th Sep 20232:11 pmPRNForm 8.3 - Instem Plc
15th Sep 202311:15 amRNSHalf-year Report
15th Sep 202310:52 amRNSForm 8.3 - Instem plc
15th Sep 202310:38 amRNSForm 8.5 (EPT/RI)
15th Sep 20239:40 amRNSForm 8.3 - Instem Plc
14th Sep 20231:31 pmGNWForm 8.3 - Instem PLC
14th Sep 202311:45 amRNSForm 8.5 (EPT/RI)
14th Sep 202310:12 amRNSForm 8.3 - Instem plc
13th Sep 20232:30 pmRNSForm 8.3 - Instem plc
13th Sep 20231:01 pmPRNForm 8.3 - Instem Plc
13th Sep 20239:04 amRNSForm 8.3 - Instem plc
12th Sep 20239:41 amRNSForm 8.5 (EPT/RI)
11th Sep 20234:30 pmRNSForm 8.3 - Instem plc
11th Sep 20239:32 amRNSForm 8.3 - Instem Plc
8th Sep 20233:00 pmBUSForm 8.3 - INS LN
8th Sep 20232:50 pmRNSForm 8.3 - Instem plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.